Proactiveinvestors United Kingdom Sareum Holdings PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Sareum Holdings PLC RSS feed en Thu, 27 Jun 2019 08:58:11 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Sareum raises £680k as it looks to take its TYK2/JAK1 inhibitors into the clinic next year ]]> https://www.proactiveinvestors.co.uk/companies/news/222839/sareum-raises-680k-as-it-looks-to-take-its-tyk2jak1-inhibitors-into-the-clinic-next-year-222839.html Sareum Holdings PLC (LON:SAR) has raised £681,000 which it will use to advance its TYK2/JAK1 inhibitor programme towards human trials.

The drug developer sold 170.37mln new shares at 0.4p as part of the fundraising, which was carried out on the online investment platform, PrimaryBid.

Sareum has mapped out preclinical programmes for its two TYK2/JAK1 inhibitors – called SDC-1801 and SDC-1802 – and is targeting human trials at some point in 2020.

READ: Sareum surges as it signals progress on preclinical programmes

TYK2/JAK1 inhibitors work by regulating the number of cytokines – a group of proteins that play an important part in boosting the immune system – produced by the body.

They have proved useful in treating cancers such as renal cell carcinoma and melanoma, as well as autoimmune diseases such as psoriasis and alopecia.

“We are pleased to have successfully completed this new fundraising, particularly the participation from retail investors, as well as the continued support from our existing shareholder base,” said chief executive Tim Mitchell.

“The funds will be used to advance our lead internal TYK2/JAK1 inhibitor programmes towards human trials.

“We believe we have the potential to generate significant value with these candidates, which represent exciting prospects in an area of increasing interest in the pharmaceutical industry.”

Sareum shares fell 27% to 0.4p in early deals on Wednesday, reflecting the discount to the issue price.

]]>
Wed, 26 Jun 2019 08:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222839/sareum-raises-680k-as-it-looks-to-take-its-tyk2jak1-inhibitors-into-the-clinic-next-year-222839.html
<![CDATA[RNS press release - Successful Fundraising ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190626070006_14124422/ Wed, 26 Jun 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190626070006_14124422/ <![CDATA[RNS press release - PrimaryBid.com Offer ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190625163105_14124153/ Tue, 25 Jun 2019 16:31:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190625163105_14124153/ <![CDATA[RNS press release - Placing to progress TYK2/JAK1 programmes ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190625163002_14124148/ Tue, 25 Jun 2019 16:30:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190625163002_14124148/ <![CDATA[News - Sareum surges as it signals progress on pre-clinical programmes ]]> https://www.proactiveinvestors.co.uk/companies/news/222041/sareum-surges-as-it-signals-progress-on-pre-clinical-programmes-222041.html Sareum Holdings PLC (LON:SAR), the specialist small molecule drug development business, has hailed the recent progress of its clinical and pre-clinical programmes.

Following last week’s announcement of preliminary efficacy data for SRA737, a cancer drug it helped to develop, the company provided the market with an update on other developments within its active pre-clinical portfolio.

READ Sareum Holdings hails early-stage efficacy data for cancer drug

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation, Sareum said.

Sareum's recent activities have focused on toxicology studies designed to gain insight into the maximum-tolerated doses of SDC-1801 and SDC-1802 in rodents.

SDC-1801, the autoimmune diseases candidate, is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; a maximum tolerated dose has yet to be reached.

In addition, the company has been exploring reliable manufacturing routes to produce each candidate for preclinical and clinical studies; such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.

Sareum Holdings PLC.

SRA737 + LGD (Low Dose Gem) + PD-L1 Immunotherapy Checkpoint Blockage.

ICB = Keytruda Merck.

100% Regression of Tumors After 21 days in SCLC Small Cell Lung Cancer.

Accounts for 15% Lung Cancers cases in the US.

Design of Human Trial in Process.$SAR.L pic.twitter.com/yRPvuwulP2

— Richard Williams (@Fadec92) June 9, 2019

"We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes,” said Dr Tim Mitchell, the chief executive officer of Sareum.

Shares in Sareum were up 4.8% in early deals.


 

]]>
Thu, 13 Jun 2019 08:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222041/sareum-surges-as-it-signals-progress-on-pre-clinical-programmes-222041.html
<![CDATA[RNS press release - Portfolio Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190613070015_14109060/ Thu, 13 Jun 2019 07:00:15 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190613070015_14109060/ <![CDATA[RNS press release - Key takeaways from SRA737 webcast at ASCO ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603160002_14096704/ Mon, 03 Jun 2019 16:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603160002_14096704/ <![CDATA[Media files - Sareum's Tim Mitchell upbeat after 'very successful' early-stage cancer trial ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13563/sareum-s-tim-mitchell-upbeat-after--very-successful--early-stage-cancer-trial-13563.html Mon, 03 Jun 2019 15:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13563/sareum-s-tim-mitchell-upbeat-after--very-successful--early-stage-cancer-trial-13563.html <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603110547_14096136/ Mon, 03 Jun 2019 11:05:47 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603110547_14096136/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603110032_14096125/ Mon, 03 Jun 2019 11:00:32 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603110032_14096125/ <![CDATA[News - Sareum Holdings hails early-stage efficacy data for cancer drug ]]> https://www.proactiveinvestors.co.uk/companies/news/221367/sareum-holdings-hails-early-stage-efficacy-data-for-cancer-drug-221367.html Sareum Holdings PLC (LON:SAR) chief executive Tim Mitchell said he was “extremely encouraged” by preliminary efficacy data released over the weekend on a drug his company helped to develop.

Most eye-catching among the headlines was the impact SRA737 had in harness with a common chemotherapy called gemcitabine in patients with anogenital cancer, where the response rate was 30%.

The latest data was taken from a phase I/II clinical trial carried out by Vancouver-based Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties.

The update, provided at American Society of Clinical Oncology (ASCO), in Chicago, also revealed that anti-cancer activity was “demonstrated across multiple indications and genetic profiles”.

“The results demonstrate the exciting potential of SRA737 in patients whose cancer type and genetic profile may confer and enhance sensitivity to this novel drug candidate, and open pathways for its advancement into the next stages of development towards registration,” said Sareum CEO Mitchell.

The shares rose 11% to 0.66p.     

Webcast feedback

Analyst Derren Nathan, of broker Hybridan, provided some interesting additional detail from the Sierra webcast earlier. He said the although strongest response came from people suffering anogentital cancers, there were “signals across multiple indications”.

Indeed, of the 139 patients assessed, 41 had the best response of “stable disease”, which means the cancer is neither decreasing nor increasing in extent or severity. Durable stable disease for a duration of four months or more was recorded in 32 people.

Nathan said images were shown on the webcast of two metastatic cancer sufferers. One, where the disease had migrated to the liver, saw the tumour size reduce by 41% after 11 cycles of the treatment.

In the other, where the disease had spread to the lung, a 26% response was observed and the lung, which had previously partially collapsed, was restored its normal function.

“To achieve these results in effectively first in man studies is really quite impressive particularly in difficult to treat patients and in the light of certain delays of treatment beginning,” Nathan said in a note.

“With further trial design improvements and, improvements in patient selection one might expect stronger signals.”

---adds webcast commentary---

 

]]>
Mon, 03 Jun 2019 07:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221367/sareum-holdings-hails-early-stage-efficacy-data-for-cancer-drug-221367.html
<![CDATA[RNS press release - Positive SRA737 data presented at ASCO ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603070007_14095153/ Mon, 03 Jun 2019 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190603070007_14095153/ <![CDATA[News - Sareum Holdings created drug to be showcased at leading cancer event next month ]]> https://www.proactiveinvestors.co.uk/companies/news/220395/sareum-holdings-created-drug-to-be-showcased-at-leading-cancer-event-next-month-220395.html The findings from clinical trials of a cancer drug developed by Sareum Holdings PLC (LON:SAR) will be showcased at a leading international cancer conference next month.

SRA737 is one of a new breed of drugs called cell cycle checkpoint inhibitors. It is currently being developed by a Canadian firm called Sierra Oncology, which has carried out phase I/II trials on people with advanced forms of the disease.

An abstract from the data which is being shared at the American Society of Clinical Oncology (ASCO) in Chicago reveals the maximum dose for SRA737 used on its own as a monotherapy was 1,000mg a day, while the recommended phase II dose is 800mg.

It also said the phase II study will treat patients who are most likely genetically to benefit from checkpoint-1 inhibitors.

Well tolerated 

A second abstract reveals SRA737 is “well tolerated” when used in combination with chemotherapy. The first-in-human study also provided proof-of-concept that the chemo “effectively potentiates” (increases the power of) SRA737.

“This novel replication stress-targeted therapy warrants further evaluation in genetically pre-defined solid tumours,” the abstract adds.

Sierra Oncology chief executive, Dr Nick Glover, said: "The two studies have enrolled patients across a range of tumour indications including a variety of prospectively selected genetic contexts, allowing us to broadly survey the cancer landscape for activity signals in response to administration of SRA737 alone and in combination with non-cytotoxic low dose gemcitabine.

“These preliminary data have also enabled us to correlate clinical findings with tumour origin and genetic signature, ascertain whether the exogenous induction of replication stress via low dose gemcitabine can enhance SRA737's activity, and determine potential next steps in the development path for SRA737."

The ASCO event runs from May 31 to June 4. The information will go on display via a poster on June 1. For more details click here.

Separately, Sierra Oncology will be hosting an analyst and investor event from 6:00-7:00am on June 3 in Chicago to discuss these clinical findings and “potential next steps in the development strategy for SRA737”.

Sareum shares rose 8.5% to 0.7p.

 --- Adds share price ---

]]>
Thu, 16 May 2019 08:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220395/sareum-holdings-created-drug-to-be-showcased-at-leading-cancer-event-next-month-220395.html
<![CDATA[RNS press release - ASCO abstracts for SRA737 published ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190516070004_14075832/ Thu, 16 May 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190516070004_14075832/ <![CDATA[RNS press release - Sareum notes Sierra Oncology Q1 2019 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190508124108_14066767/ Wed, 08 May 2019 12:41:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190508124108_14066767/ <![CDATA[RNS press release - Sareum to Present at BioTrinity 2019 in London ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190430070020_14056425/ Tue, 30 Apr 2019 07:00:20 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190430070020_14056425/ <![CDATA[News - Sareum Holdings jumps as it says new data on cancer drug to be released at top conference ]]> https://www.proactiveinvestors.co.uk/companies/news/218923/sareum-holdings-jumps-as-it-says-new-data-on-cancer-drug-to-be-released-at-top-conference-218923.html Sareum Holdings PLC (LON:SAR) shares jumped on Tuesday as the firm said data from a potential cancer drug it developed will be showcased at the world’s leading oncology conference.

Updated results from a Phase I/IIa studies carried out on SRA737 by licensing partner Sierra Oncology will be delivered in the form of two abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1.

The Sareum-discovered drug candidate is what’s known as a checkpoint kinase 1 (CHK1) inhibitor.

CHK1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally by chemotherapy or radiotherapy.

The new treatment is being trialled in women with ovarian cancer, both as a single therapy and in harness with chemotherapy called gemcitabine.

The ASCO abstracts cover new data on the two approaches to treating the killer disease.

In afternoon trading, Sareum shares were 7.1% higher at 0.75p.

 -- Adds share price --

]]>
Tue, 23 Apr 2019 07:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218923/sareum-holdings-jumps-as-it-says-new-data-on-cancer-drug-to-be-released-at-top-conference-218923.html
<![CDATA[RNS press release - SRA737 Phase I/IIa data to be presented at ASCO ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190423070006_14047483/ Tue, 23 Apr 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190423070006_14047483/ <![CDATA[News - Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models ]]> https://www.proactiveinvestors.co.uk/companies/news/217748/sareums-flagship-chk1-inhibitor-shows-serious-lung-cancer-potential-in-mouse-models-217748.html Sareum Holdings Plc (LON:SAR) shot higher on Tuesday after data presented at a massive industry conference showed that its flagship Checkpoint 1 inhibitor was able to remove any evidence of lung cancer in mice.

When combined with low-dose gemcitabine – commonly-prescribed in chemotherapy – and an anti-PD-L1 immunotherapy, SRA737 demonstrated “dramatic anti-tumour activity”, Sareum said.

WATCH: Sareum boss looks ahead to critical Phase II data from SRA737

All ten of the mice with small cell lung cancer (SCLC) showed tumour regression at the end of the 21-day treatment period. Eight of the mice showed sustained complete response after a further 39 days without receiving any more treatment.

A complete response doesn’t mean cured, but it is the best result that can be reported and means there is no evidence of the disease.

The data, which was presented at the American Association of Cancer Research in Atlanta, suggests this combination of SRA737, LDG and an anti-PD-L1 immunotherapy “may represent the optimal implementation of these agents,” said Sareum.

‘Very exciting’

“The model data presented are very exciting with all examples treated with SRA737, LDG and anti-PD-L1 showing tumour regression and 80% having a complete response, with no detectable cancer,” said Sareum chief executive Tim Mitchell.

“This provides a clear early demonstration of the potential of SRA737+LDG to enhance anti-PD-L1 immunotherapy in small cell lung cancer, a cancer type where such immunotherapies have shown limited benefit.”

He added: “We will follow the progress of studies using this novel combination approach with great interest.”

Sareum shares jumped 6.4% to 0.81p on Tuesday.

]]>
Tue, 02 Apr 2019 09:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217748/sareums-flagship-chk1-inhibitor-shows-serious-lung-cancer-potential-in-mouse-models-217748.html
<![CDATA[RNS press release - Preclinical Data for SRA737 Presented at AACR 2019 ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190402070017_14024557/ Tue, 02 Apr 2019 07:00:17 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190402070017_14024557/ <![CDATA[RNS press release - Sareum Holdings PLC Issue of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190312070004_13998080/ Tue, 12 Mar 2019 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190312070004_13998080/ <![CDATA[Media files - Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html Mon, 11 Mar 2019 13:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html <![CDATA[News - Sareum boss “very pleased” with progress of flagship Chk1 inhibitor ]]> https://www.proactiveinvestors.co.uk/companies/news/215697/sareum-boss-very-pleased-with-progress-of-flagship-chk1-inhibitor-215697.html Sareum Holdings Plc (LON:SAR) boss Tim Mitchell has said he is “very pleased” with the progress being made by Sierra Oncology – its partner which is taking SRA737 through the clinic.

SRA737, which is a checkpoint kinase 1 (Chk1) inhibitor, was originally discovered by Sareum before Sierra licensed it back in 2016.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data

Sierra is currently using SRA737 in in two early-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Preliminary data from these trials are expected within the next few months.

Last week, Sierra published pre-clinical data which showed that SRA7737 had a “dramatic enhancement” in anti-tumour activity in a lung cancer model when combined with immunotherapy and low dose gemcitabine.

“We are very pleased with the progress that Sierra has made advancing its clinical programmes with SRA737 in recent months and we look forward to seeing preliminary data from these trials, expected in the first half of 2019,” said Mitchell.

“We are also encouraged by the preclinical work that Sierra and co-workers are conducting to support Chk1 inhibition by SRA737 as an attractive mechanism in combination with other leading cancer drug classes, including immuno-oncology drugs and PARP inhibitors.”

TYK2/JAK1 programme also progressing nicely

Away from SRA737, Sareum has invested a lot of time in its TYK2/JAK1 programme.

It has recently selected two molecules – one targeting autoimmune diseases and theother targeting certain types of leukaemia, lymphoma and solid tumours – for preclinical development.

Mitchell added: “With regard to our proprietary programmes, the selection of SDC-1801 and SDC-1802 as preclinical candidates were important achievements and both are now advancing through preclinical programmes with a view to entering clinical trials in 2020.

“We believe that these compounds have excellent qualities and target a mechanism that is gaining credibility and generating growing interest in the pharmaceutical industry. Advancing these two programmes as quickly and as rigorously as possible is the focus of all our current resources.”

£1.5mln cash in the bank

For the six months ended 31 December, Sareum made a loss of £764,000 (H1 17: £722,000).

After raising £850,000 back in November, the company finished the period with £1.54mln of cash in the bank (H1 17: £2.17mln).

Sareum shares fell 6.5% to 0.72p in early deals on Monday.

]]>
Mon, 04 Mar 2019 08:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215697/sareum-boss-very-pleased-with-progress-of-flagship-chk1-inhibitor-215697.html
<![CDATA[RNS press release - HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190304070006_13988213/ Mon, 04 Mar 2019 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190304070006_13988213/ <![CDATA[RNS press release - Sierra Oncology has reported its 2018 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228140438_13985760/ Thu, 28 Feb 2019 14:04:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228140438_13985760/ <![CDATA[News - Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data ]]> https://www.proactiveinvestors.co.uk/companies/news/215509/sareum-surges-as-its-flagship-chk1-inhibitor-continues-to-produce-encouraging-data-215509.html Sareum Holdings PLC (LON:SAR) surged on Thursday morning as its SRA737 checkpoint kinase 1 (Chk1) inhibitor continues to impress.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum primed for progress

Sierra Oncology Inc (NASDAQ:SRRA), the US firm which has licensed SRA737, has published pre-clinical data showing it had a “dramatic enhancement” in anti-tumour activity when combined with immunotherapy and low dose gemcitabine – one of the most commonly prescribed chemotherapies.

“These new studies reveal a striking immunomodulatory effect of SRA737 + LDG that results in some of the most profound synergistic activity with anti-PD-L1 therapy that we have observed in this model,” said Lauren Byers, associate professor at the University of Texas MD Anderson cancer center.

“We are excited by the potential clinical translatability of these findings and their possible broader impact on immune checkpoint blockade strategies.”

Research house Hybridan added: “This three-way combination is another potential addition to SRA737’s development programme which stands to generate significant further milestones and in due course royalties for Sareum.”

The data is being presented at the American Association of Cancer Research annual meeting in Atlanta, Georgia next month.

In afternoon trading in London, Sareum shares were 12.5% higher 0.68p.

Reporting results today, Sierra CEO Nick Glover commented: "We have enrolled a substantial number of patients into the two ongoing trials for our oral Chk1 inhibitor, SRA737, and remain on track to report clinical data from these studies in the first half of 2019."

In pre-market trading in New York, Sierra Oncology shares were 11.5% higher at $2.0299.

 -- Adds Sierra comment, share price --

]]>
Thu, 28 Feb 2019 09:31:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215509/sareum-surges-as-its-flagship-chk1-inhibitor-continues-to-produce-encouraging-data-215509.html
<![CDATA[RNS press release - New SRA737 preclin data to be presented at AACR ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228081444_13984977/ Thu, 28 Feb 2019 08:14:44 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190228081444_13984977/ <![CDATA[News - Sareum Holdings primed for progress ]]> https://www.proactiveinvestors.co.uk/companies/news/215154/sareum-holdings-primed-for-progress-215154.html Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology. There are a further two trials planned. The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.

SRA737

This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage. Sareum’s NASDAQ-listed partner is currently refining trials of the drug following the emergence of new data. It will focus efforts on a form of ovarian cancer. This “reprioritising and enlarging” of the ongoing Phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019. Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.

What else does Sareum have?

Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020. Both are members of the Janus Kinase (JAK) family and specifically are TYK2/JAK1 kinases. They work by inhibiting the activity of one or more of the Janus kinase family of enzymes.

What the broker says

Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space.”

]]>
Fri, 22 Feb 2019 15:42:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215154/sareum-holdings-primed-for-progress-215154.html
<![CDATA[RNS press release - Sierra Oncology to present SRA737 at DDR Tx Summit ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190123133833_13944459/ Wed, 23 Jan 2019 13:38:33 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20190123133833_13944459/ <![CDATA[News - Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal ]]> https://www.proactiveinvestors.co.uk/companies/news/211924/sareum-holdings-shares-soar-as-hybridan-spotlights-read-across-from-big-us-pharma-takeover-deal-211924.html Sareum Holdings Plc (LON:SAR) saw its shares soar higher on Thursday as analysts at Hybridan spotlighted a read-across from the launch of big pharma takeover deal in the US.

The small-cap broker’s analysts noted that Bristol-Myers Squibb Co. (NYSE:BMY) has agreed to acquire Celgene Corp (NASDAQ:CELG) for US$74bn, with the combined entity to have six expected near-term product launches, representing more than US$15bn in revenue potential.

READ: Sareum Holdings chairman says drug discovery group is making progress

They pointed out that includes Bristol-Myers Squibb’s TYK2 (Tyrosine Kinase 2) protein-coding gene candidate, an inhibitor which is used as a treatment for autoimmune conditions.

The analysts noted that they have previously mused that the inhibitive qualities of Sareum’s two candidates in the same space could mean that, along with other qualities, its assets could emerge as best in class.

They said their review of the clinical evidence so far suggests that Sareum’s JAK1 (Janus kinase) inhibitor – which is one of the same family as TYK2 - could provide some additional efficacy particularly in autoimmune conditions such as Psoriasis.

The analysts concluded that even with today’s share price jump – up 19% to 0.62p in late afternoon trading -- Sareum’s market cap of just £18mln makes the firm “arguably a bargain target for the relatively large group of Biotech and Pharma companies interested in TYK2 and the wider JAK inhibitor space.”

]]>
Thu, 03 Jan 2019 15:49:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211924/sareum-holdings-shares-soar-as-hybridan-spotlights-read-across-from-big-us-pharma-takeover-deal-211924.html
<![CDATA[RNS press release - Results of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218123540_13908101/ Tue, 18 Dec 2018 12:35:40 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218123540_13908101/ <![CDATA[News - Sareum Holdings chairman says drug discovery group is making progress ]]> https://www.proactiveinvestors.co.uk/companies/news/211380/sareum-holdings-chairman-says-drug-discovery-group-is-making-progress-211380.html Drug discovery group Sareum Holdings Plc (LON:SAR) will tell investors 2018 has been a year of significant progress.

At the company’s annual meeting, being held in the City of London, chairman Dr Stephen Parker will point to the progress of SRA737, which has been licensed to Sierra Oncology.

Sareum’s NASDAQ-listed partner is currently refining trials of the drug as new data emerged and is prioritising development on high-grade serous ovarian cancer.

Clincial data due by mid-next year

This “reprioritising and enlarging” of the ongoing phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019.

Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.

An early-stage trial of SRA737 in patients taking the drug on its own is being carried out at 15 hospitals around the UK and is expected to be concluded in April 2020.

Also ongoing are studies using the treatment in combination with low-dose chemotherapy, while there are plans to use SRA737 in harness with a type of cancer therapy called a PARP inhibitor.

Earlier in the pipeline 

Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020.

During the year, Sareum bolstered its governance by appointing two new independent directors to the board - Dr Mike Owen and Clive Birch.

Financially, the group was sitting on around £1.4mln in October and has since gone on to raise a further £850,000.

“The board of directors believes that 2018 has consolidated the progress and increasing maturity reported last year,” chairman Parker will tell investors.

“I would like to thank our shareholders, collaboration partners, suppliers, contractors and other stakeholders for their continued support and look forward to providing further updates on progress in 2019.”

]]>
Tue, 18 Dec 2018 07:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211380/sareum-holdings-chairman-says-drug-discovery-group-is-making-progress-211380.html
<![CDATA[RNS press release - AGM Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218070003_13906997/ Tue, 18 Dec 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181218070003_13906997/ <![CDATA[RNS press release - Amendment to Preclinical Efficacy Announcement ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130111754_13887116/ Fri, 30 Nov 2018 11:17:54 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130111754_13887116/ <![CDATA[News - Sareum’s SRA737 Chk1 inhibitor impresses once again ]]> https://www.proactiveinvestors.co.uk/companies/news/210289/sareums-sra737-chk1-inhibitor-impresses-once-again-210289.html Sareum Holdings Plc (LON:SAR) shares were in demand on Friday morning after Sierra Oncology, the US firm which has licensed Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate, published new data overnight.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

In data presented at an industry conference in Miami on Thursday, SRA737 demonstrated “clear anti-tumour activity” in a preclinical model of small cell lung cancer.

READ: SRA737 could have potential in ovarian cancer

 “We are encouraged by the findings of this study, which was presented at AACR,” said Sareum chief executive Tim Mitchell.

“It showed SRA737 activated the innate immune signalling Stimulator of Interferon Genes (STING) pathway and demonstrated clear anti-tumour activity in an immunocompetent preclinical model of small cell lung cancer.

“These are important findings as SCLC remains a significant unmet need and one where immunotherapies have yielded limited efficacy. These encouraging preclinical results highlight an additional potential opportunity for SRA737 that warrants further evaluation.”

Research house Hybridan added: “This data bodes well for a potential immunotherapy combination study in humans, which if successful further augments the potential scale of future royalties to Sareum, as well as the likelihood of further success milestones.”

Shares rose 5.7% to 0.74p in early deals on Friday.

]]>
Fri, 30 Nov 2018 08:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210289/sareums-sra737-chk1-inhibitor-impresses-once-again-210289.html
<![CDATA[RNS press release - Preclinical Efficacy for Immunotherapy Combination ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130074505_13886558/ Fri, 30 Nov 2018 07:45:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181130074505_13886558/ <![CDATA[News - Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer ]]> https://www.proactiveinvestors.co.uk/companies/news/209282/latest-data-suggests-sareums-sra737-chk1-inhibitor-has-potential-in-ovarian-cancer-209282.html Sareum Holdings Plc’s (LON:SAR) SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate has potential in certain types of ovarian cancer, according to Sierra Oncology, the US firm which has licensed the compound.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Preliminary results from SRA737 clinical trials due in H1 2019

Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer (HGSOC).

Sareum said the in vivo – i.e. in a living organism – data support the ongoing phase I/II monotherapy clinical trial of the compound, which is enrolling patients with these HGSOC subtypes.

The AIM company also reckons the data supports the idea that SRA737 could be useful when combined with low-dose gemcitabine – one of the most commonly prescribed chemotherapies – or PARP inhibitors, which stop cancer cells repairing themselves.

Sareum boss “encouraged” by data

An early-stage study of the compound with low-dose gemcitabine is already underway, while Sierra is preparing for a trial which will see SRA737 partnered with niraparib, a PARP inhibitor.

“The data presented today continue to provide evidence that SRA737 has potential in ovarian cancer where the tumours exhibit defective cell cycle checkpoint control and replicative stress, and which is identifiable by genetic markers,” said Sareum chief executive Tim Mitchell.

“This represents a significant proportion of HGSOC patients who currently have few treatment options. We are encouraged by the new data, which supports the rationale for Sierra's clinical study with SRA737 as a monotherapy and look forward to updates from the ongoing clinical trials in the first half of 2019.”

Sareum shares rose 4.8% on the back of the announcement to 0.81p.

]]>
Thu, 15 Nov 2018 11:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209282/latest-data-suggests-sareums-sra737-chk1-inhibitor-has-potential-in-ovarian-cancer-209282.html
<![CDATA[RNS press release - Preclinical Data for SRA737 in Ovarian Cancer ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181115102427_13868402/ Thu, 15 Nov 2018 10:24:27 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181115102427_13868402/ <![CDATA[RNS press release - AGM NOTICE ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181114070004_13865884/ Wed, 14 Nov 2018 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181114070004_13865884/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181113070019_13864242/ Tue, 13 Nov 2018 07:00:19 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181113070019_13864242/ <![CDATA[News - Preliminary results from Sierra Oncology’s clinical trials of Sareum’s SRA737 compound due in H1 2019 ]]> https://www.proactiveinvestors.co.uk/companies/news/208850/preliminary-results-from-sierra-oncologys-clinical-trials-of-sareums-sra737-compound-due-in-h1-2019-208850.html Preliminary results from two early-stage trials featuring Sareum Holdings PLC’s (LON:SAR) SRA737 checkpoint kinase 1 (Chk1) inhibitor cancer candidate are due to be published in the first half of 2019.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum secures funding for drug programme

US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update it has made “substantial progress” with its two clinical development programmes for the compound.

Sierra is currently undertaking a Phase I/II monotherapy trial – i.e. SRA737 on its own – of the drug in patients with advanced cancer, as well as another Phase I/II study in which SRA737 is being combined with low-dose gemcitabine, one of the most commonly prescribed chemotherapies.

The NASDAQ-listed company said it has made “substantial progress” in recruiting patients with high grade serous ovarian cancer and that it expects to report preliminary efficacy results from these trials in the first half of next year.

Sierra has also been busy preparing for a third trial of SRA737 in combination with niraparib, a PARP inhibitor which stops cancer cells from repairing themselves, in prostate cancer patients, which is expected to begin within the next few months.

]]>
Thu, 08 Nov 2018 13:20:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208850/preliminary-results-from-sierra-oncologys-clinical-trials-of-sareums-sra737-compound-due-in-h1-2019-208850.html
<![CDATA[RNS press release - Sierra Oncology Q3 2018 Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181108122800_13860401/ Thu, 08 Nov 2018 12:28:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181108122800_13860401/ <![CDATA[News - Sareum secures funding for drug programme ]]> https://www.proactiveinvestors.co.uk/companies/news/207911/sareum-secures-funding-for-drug-programme-207911.html Sareum Holdings Plc (LON:SAR) said it had completed a share placing that has raised £850,000.

The proceeds will be used for working capital purposes and to fund the development of its TYK2/JAK1 targets, which are being developed to treat autoimmune disease and cancer.

READ: Sareum selects potential anti-cancer molecule for further development

“We believe we have strong candidates with optimised profiles in these areas and are focused on advancing these into preclinical development towards clinical trials,” said chief executive, Dr Tim Mitchell.

“These new funds, added to our current cash, will enable us to advance these studies and build up the evidence required to facilitate a licensing agreement at an optimal value."

The stock, which closed Thursday at 0.78p, was sold in placing for 0.65p a share.

]]>
Fri, 26 Oct 2018 07:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207911/sareum-secures-funding-for-drug-programme-207911.html
<![CDATA[RNS press release - Completion of Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181026070003_13843283/ Fri, 26 Oct 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181026070003_13843283/ <![CDATA[RNS press release - FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181001070004_13810059/ Mon, 01 Oct 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20181001070004_13810059/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180927130316_13807373/ Thu, 27 Sep 2018 13:03:16 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180927130316_13807373/ <![CDATA[News - Sareum selects potential anti-cancer molecule for further development ]]> https://www.proactiveinvestors.co.uk/companies/news/205729/sareum-selects-potential-anti-cancer-molecule-for-further-development-205729.html Sareum Holdings Plc (LON:SAR) has selected another candidate molecule from its TYK2 inhibitor programme to take through the clinic, this time as a potential therapy for certain cancers.

Earlier this month, the AIM company went with SDC-1801 as a “potentially best-in-class” treatment for autoimmune diseases.

READ: Sareum to further develop ‘potential best-in-class’ autoimmune disease treatment

It has now chosen SDC-1802 which has shown “compelling efficacy” in blocking cancer cell proliferation in leukaemia disease models, while Sareum thinks it could also be used to treat certain kidney, colon, skin and pancreatic cancers.

The compound has the potential for once-daily oral dosing and a good early safety profile, Sareum added.

SDC-1802 works by targeting the TYK2 and JAK1 enzymes, which are known to have roles in promoting cancer growth.

Those enzymes are also involved in the pro-inflammatory responses in autoimmune diseases, which is why Sareum thinks SDC-1802 also has the potential to act as a backup molecule to SDC-1801.

Clinical trials in 2020

“We are very pleased to have formally selected lead candidates from our TYK2 inhibitor programme for both cancer and autoimmune diseases,” said chief executive Tim Mitchell.

“The candidates are distinct small molecules with attractive and highly competitive profiles for development in their respective indications.”

He added: “Both have produced exciting results in preclinical disease models and we believe present valuable opportunities for licensing and/or further development.

“Our focus is now to advance both candidates into clinical studies, which we anticipate beginning in 2020.”

Sareum shares were down 1.3% to 0.76p shortly after the opening bell on Wednesday.

]]>
Wed, 26 Sep 2018 08:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205729/sareum-selects-potential-anti-cancer-molecule-for-further-development-205729.html
<![CDATA[RNS press release - TYK2/JAK1 selected for certain cancers ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180926070003_13804513/ Wed, 26 Sep 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180926070003_13804513/ <![CDATA[News - Sareum reports “strong progress” made with in-house and out-licensed drug programmes ]]> https://www.proactiveinvestors.co.uk/companies/news/204614/sareum-reports-strong-progress-made-with-in-house-and-out-licensed-drug-programmes-204614.html Sareum Holdings Plc (LON:SAR) has highlighted the progress made by its in-house and out-licensed drug programmes over the past year.

US firm Sierra Oncology, which is the licence holder of Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor cancer candidate, has made “strong progress” with its two clinical development programmes for the Chk1 inhibitor.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

Two Sierra studies ongoing, one to start soon

A phase I/II monotherapy trial – i.e. SRA737 on its own – of the drug in patients with advanced cancer was expanded by 170 people.

The other phase study, also phase I/II, sees SRA737 combined with low-dose gemcitabine, one of the most commonly prescribed chemotherapies.

This trial was modified to include 80 genetically defined patients in four cancer indications, with a target cohort of ovarian cancer patients replacing the originally proposed bladder cancer patients

The third trial of SRA737 in combination with niraparib, a PARP inhibitor which stops cancer cells from repairing themselves, in prostate cancer patients is expected to begin within the next few months.

Sierra is also in the process of designing a trial for SRA737 and immune checkpoint blockade, with preclinical data providing “evidence of synergy” for this combination.

Good internal progress, too

Sareum has also reported the “good progress” made with advancing its internal TYK2/JAK1 inhibitor programmes.

The company revealed earlier this week that it has selected a candidate molecule to take through the clinic which it thinks could become the new, "potentially best-in-class" treatment for autoimmune diseases.

SDC-1801 had shown “compelling activity” in disease models of psoriasis and rheumatoid arthritis, while AIM-listed Sareum also noted the potential for once-daily oral dosing and a good early safety profile.

The firm is also in the final stages of selecting a TYK2/JAK1 inhibitor targeting cancer indications.

READ: Sareum takes back promising technology

On top of all that, at the start of summer Sareum regained the rights to a pre-clinical technology that it reckons could have the potential to treat acute myeloid leukaemia and other blood-borne cancers.

The Aurora+FLT3 kinase inhibitors were handed back by Hebei Medical University Biomedical Engineering Center (HMUBEC), a Chinese group, which encountered "ongoing issues relating to the intravenous formulation".

The plan is to find another partner for this programme while it focuses time and money on its TYK2 inhibitor candidates.

£1.4mln in the bank

The company ended the fiscal year with just under £1.40mln in the bank, having raised an additional £700,000 last November.

Investors who backed that funding round at 0.7p a share are now sitting on a small profit with the shares up to 0.75p in early deals on Tuesday.

As is common for companies at this formative stage of their development, Sareum was loss-making – to the tune of £1.47mln.

]]>
Tue, 11 Sep 2018 08:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204614/sareum-reports-strong-progress-made-with-in-house-and-out-licensed-drug-programmes-204614.html
<![CDATA[RNS press release - Pre-Close Trading Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180911070009_13785521/ Tue, 11 Sep 2018 07:00:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/885/LSE20180911070009_13785521/